Sunesis Pharmaceuticals Inc. will use its Tethering technology to discover therapeutics for inflammatory and autoimmune diseases in a collaboration with Biogen Inc. (BioWorld Today)
Sunesis Pharmaceuticals Inc. will use its Tethering technology to discover therapeutics for inflammatory and autoimmune diseases in a collaboration with Biogen Inc. (BioWorld Today)
Theravance Inc. stands to make up to $545 million in a deal with GlaxoSmithKline plc to pool their respective long-acting beta 2 agonists to develop treatments for respiratory diseases such as asthma and chronic obstructive pulmonary disease. (BioWorld Today)
Theravance Inc. stands to make up to $545 million in a deal with GlaxoSmithKline plc to pool their respective long-acting beta 2 agonists to develop treatments for respiratory diseases such as asthma and chronic obstructive pulmonary disease. (BioWorld Today)
